Andere Sprachen Alvotech

Aktien

ALVO

LU2458332611

ALVO

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:21:37 30.04.2024			% 5 Tage	% 1. Jan.
14.6 ^USD	+3.22%		+6.15%	+23.26%

14:03	Alvotech wird Humira-Biosimilar Adalimumab-ryvk für Quallent herstellen	MT
25.04.	Cigna bietet Humira-Rivalen mit $0 Zuzahlung in Spezialapotheke an	RE

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	17:33
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	14:03
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	10:00
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar	26.04.
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	25.04.
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi	25.04.
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	24.04.
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)	24.04.
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi	24.04.
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira	22.04.
Sector Update: Health Care Stocks Advance Late Afternoon	19.04.
Sector Update: Health Care Stocks Rise Friday Afternoon	19.04.
Sector Update: Health Care	19.04.
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19.04.
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19.04.
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)	19.04.
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®	19.04.
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17.04.
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16.04.
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alvotech

Aktien

ALVO

LU2458332611

ALVO

Andere Sprachen

Filter